Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Bear Bile Powder Improves Ulcerative Colitis by Protecting the Intestinal Mechanical Barrier and Regulating Intestinal Flora

Author(s): Zi-Bo Liu, Xun Ye, Chun-Jie Wu* and Da-Neng Wei*

Volume 30, Issue 19, 2024

Published on: 26 April, 2024

Page: [1530 - 1540] Pages: 11

DOI: 10.2174/0113816128294893240403074953

Price: $65

conference banner
Abstract

Background: Bear Bile Powder (BBP) is a traditional Chinese medicine. It has been widely used in clinical practices and has shown a good anti-inflammatory effect. However, its effectiveness in treating Ulcerative Colitis (UC) has not yet been studied.

Objective: To explore the therapeutic effect of BBP on ulcerative colitis and its potential mechanism by combining acute ulcerative colitis mouse models and comprehensively observing various physiological and biochemical indexes of mice.

Methods: The acute ulcerative colitis model was induced by drinking water containing dextran sulfate sodium salt (DSS) for 7 days. Studies were divided into Control, DSS, DSS+ Sulfasalazine (SASP, 450 mg/kg), and DSS + bear bile powder group (BBP, 320 mg/kg). The Disease Activity Index (DAI) and colonic tissue damage of mice were evaluated. Tissue immunofluorescence and western blot were used to determine related tight Junction Proteins (TJs), and 16S V34 amplicon was used to analyze intestinal microorganisms. The therapeutic effect of BBP on ulcerative colitis model mice was studied comprehensively.

Results: After treatment, BBP can significantly improve the physiological condition of acute UC mice and reduce DAI fraction. Compared with the DSS group, the BBP group significantly increased the colon length and significantly decreased the injury fraction of acute UC mice. Regarding the intestinal mechanical barrier, BBP significantly increased the expression of ZO-1, Occludin, and Claudin 1 protein in colon tissue. In terms of microbial community, the intestinal microbial diversity of mice decreased after the administration of BBP, but there was no significant difference in structural composition between the BBP group and the Control group. By comparing the four groups of species with significant differences, it was found that the BBP group significantly reduced the abundance of specific harmful microorganisms at the order, family, genus, and species levels.

Conclusion: Oral administration of a certain dose of BBP can significantly improve the symptoms of ulcerative colitis in mice. Part of the reason may be that it increases the expression of tight junction proteins, regulates specific flora in the intestine of mice, and maintains intestinal barrier homeostasis. In the future, the clinical application value of BBP will be explored, and BBP will be developed as a drug with the potential to treat UC and alleviate the pain of UC patients.

« Previous
[1]
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021; 18(1): 56-66.
[http://dx.doi.org/10.1038/s41575-020-00360-x] [PMID: 33033392]
[2]
Narula N, Wong ECL, Dehghan M, et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study. BMJ 2021; 374(1554): n1554.
[http://dx.doi.org/10.1136/bmj.n1554] [PMID: 34261638]
[3]
Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: Epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol 2019; 16(4): 247-59.
[http://dx.doi.org/10.1038/s41575-018-0091-9] [PMID: 30531816]
[4]
Eisenstein M. Gut reaction. Nature 2018; 563(7730): S34-5.
[http://dx.doi.org/10.1038/d41586-018-07277-1] [PMID: 30405233]
[5]
Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers 2020; 6(1): 74.
[http://dx.doi.org/10.1038/s41572-020-0205-x] [PMID: 32913180]
[6]
Chi SG. Advances in synthetic methods and pharmacology of major chemical constituents of bear bile. Strait Pharmaceut J 2008; 2008: 5-8.
[7]
Zhu H, Wang G, Bai Y, et al. Natural bear bile powder suppresses neuroinflammation in lipopolysaccharide-treated mice via regulating TGR5/AKT/NF-κB signaling pathway. J Ethnopharmacol 2022; 289: 115063.
[http://dx.doi.org/10.1016/j.jep.2022.115063] [PMID: 35149130]
[8]
Wang L, Bai Y, Tao Y, et al. Bear bile powder alleviates Parkinson’s disease-like behavior in mice by inhibiting astrocyte-mediated neuroinflammation. Chin J Nat Med 2023; 21(9): 710-20.
[http://dx.doi.org/10.1016/S1875-5364(23)60449-2] [PMID: 37777320]
[9]
Lin GH. Effects of heat-clearing and detoxifying traditional Chinese medicine bear bile powder on intestinal flora in healthy people. Tianjin Uni Trad Chin Med 2020; 2020: 56.
[10]
Li Y, Xiao H, Hu D, et al. Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. Pharmacol Res 2016; 110: 227-39.
[http://dx.doi.org/10.1016/j.phrs.2016.02.010] [PMID: 26969793]
[11]
Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend Your Fences. Cell Mol Gastroenterol Hepatol 2017; 4(1): 33-46.
[http://dx.doi.org/10.1016/j.jcmgh.2017.03.007] [PMID: 28560287]
[12]
Wang J, Xiong AZ, Cheng RR, et al. Systematic analysis of chemical composition of drained bear bile powder from different sources. Zhongguo Zhongyao Zazhi 2018; 43: 2326-32.
[http://dx.doi.org/10.19540/j.cnki.cjcmm.20180125.001] [PMID: 29945386]
[13]
Cao SS, Zimmermann EM, Chuang BM, et al. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology 2013; 144(5): 989-1000.e6.
[http://dx.doi.org/10.1053/j.gastro.2013.01.023] [PMID: 23336977]
[14]
Van den Bossche L, Hindryckx P, Devisscher L, et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol 2017; 83(7): e02766-16.
[http://dx.doi.org/10.1128/AEM.02766-16] [PMID: 28115375]
[15]
Hao W, Hao C, Wu C, Xu Y, Jin C. Aluminum induced intestinal dysfunction via mechanical, immune, chemical and biological barriers. Chemosphere 2022; 288(Pt 2): 132556.
[http://dx.doi.org/10.1016/j.chemosphere.2021.132556] [PMID: 34648793]
[16]
Groschwitz KR, Hogan SP. Intestinal barrier function: Molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124(1): 3-20.
[http://dx.doi.org/10.1016/j.jaci.2009.05.038] [PMID: 19560575]
[17]
Kumar N, Sahoo NK, Mehan S, verma B. The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis. Mult Scler Relat Disord 2023; 71: 104547.
[http://dx.doi.org/10.1016/j.msard.2023.104547] [PMID: 36805171]
[18]
Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol 2020; 145(1): 16-27.
[http://dx.doi.org/10.1016/j.jaci.2019.11.003]
[19]
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015; 21(29): 8787-803.
[http://dx.doi.org/10.3748/wjg.v21.i29.8787] [PMID: 26269668]
[20]
Caruso R, Lo BC, Núñez G. Host–microbiota interactions in inflammatory bowel disease. Nat Rev Immunol 2020; 20(7): 411-26.
[http://dx.doi.org/10.1038/s41577-019-0268-7] [PMID: 32005980]
[21]
Ke H, Li F, Deng W, et al. Metformin exerts anti-inflammatory and mucus barrier protective effects by enriching Akkermansia muciniphila in mice with ulcerative colitis. Front Pharmacol 2021; 12: 726707.
[http://dx.doi.org/10.3389/fphar.2021.726707] [PMID: 34658866]
[22]
Cui L, Guan X, Ding W, et al. Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. Int J Biol Macromol 2021; 166: 1035-45.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.10.259] [PMID: 33157130]
[23]
Zhu Y, Zhao Q, Huang Q, et al. Nuciferine regulates immune function and gut microbiota in DSS-induced ulcerative colitis. Front Vet Sci 2022; 9: 939377.
[http://dx.doi.org/10.3389/fvets.2022.939377] [PMID: 35909691]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy